Wrapping Up 2024: A Year in Content
As we near the end of the year, it’s the perfect time to reflect on the content we’ve shared with you throughout 2024. From thought-provoking articles to expert-led webinars, and everything in between, it’s been a year full of insights, inspiration, and impactful content that resonated with all of you.
Whether you missed a post or just want to relive some of our great content, we’ve got you covered with a round-up of everything you loved in 2024.
KOL Spotlights
Dr. Elsa Shapiro, Dr. Julie Eisengart, and Dr. Paul Harmatz
Finding the best metrics for pediatric neurogenetic trial
Dr. Shapiro, Dr. Eisengart, and Dr. Harmatz discussed the neurogenetic illnesses that influence brain function in up to three percent of children, and the difficulty finding instruments sensitive enough to identify changes in their developmental skills. Gain more insight into the difficulties associated with therapy in these trial settings.
Dr. John Harrison
Testing cognition in Alzheimer’s Disease clinical trials
What’s holding back breakthroughs in finding new treatments for Alzheimer’s Disease (AD)? The number of adults living with AD is expected to top 14 million by 2060, but unfortunately, current treatments and clinical trials for new treatments have not been successful.
Watch this on-demand webinar with subject matter expert Dr. John Harrison and gain insight into why assessment tools fail, how better endpoint measures can help advance AD research, and strategies for selecting appropriate scales.
Growth Scale Values (GSVs) Resources
Play
GSVs, a type of score that represents the absolute performance on a test, have been used for more than 50 years. Many of our assessments, such as the Bayley Scales of Infant and Toddler Development™ (Bayley™-4) and Vineland™-3, have the capability to develop GSVs.
This newly created resource page features an infographic and additional technical resources about GSV development, interpretation, and out-of-level testing.
Blogs
Finnish localization case study
How a partner collaboration determined an effective multifaceted translation approach
In 2023, Pearson and Lionbridge encountered challenges translating the Bayley Scales into Finnish (fiFI) due to differences in gendered and possessive pronouns, as well as verb tenses between Finnish and English. To address this, an interdisciplinary team worked to create a translation that preserved the tool's validity, cultural relevance, and global applicability.
Learn how this translation was achieved by reading the blog.
Read the blog
Growth Scale Values are gaining traction in clinical trials
Although Growth Scale Values (GSVs) have been used for more than 50 years, they are now gaining popularity as a more precise way to measure outcomes in clinical trials. Unlike raw scores or age equivalents, GSVs offer a continuous, interval-based score sensitive to small but meaningful changes. In rare-disease studies, GSVs are considered superior because of their ability to provide a sensitive measure of change and increased precision.
Want to learn more?
Read the blog
Thought leadership
Successful COA selection paves the path to drug development
COAs must be reliable, valid, and aligned with patient health concerns, and choosing the right one is critical for evaluating a drug’s benefits and risks. An inappropriate COA can lead to misleading results, regulatory delays, or higher patient dropout rates.
For anyone involved in the development of novel treatments, understanding the importance of COA selection is key to advancing therapies effectively and efficiently. Read this article by Biopharma Dive and Pharma Research Services to learn how the right COA can streamline your clinical trials and enhance regulatory success.
Acknowledging comorbidities in trial design is essential for successful outcomes
This article by Biopharma Dive and Pharma Research Services focuses on comorbidities and the importance of including diverse participants in clinical trials. It also explains why rigid protocols are hurting trial outcomes, not helping, and why adaptive approaches are needed.
As we wrap up 2024, we want to take a moment to express our gratitude for your continued support and engagement. Stay tuned for what’s ahead – we can’t wait to share more great content with you in 2025!